ValuEngine upgraded shares of VIVUS (NASDAQ:VVUS) from a hold rating to a buy rating in a research report released on Thursday morning.
Separately, Zacks Investment Research raised VIVUS from a sell rating to a hold rating in a report on Monday, October 8th.
VVUS stock opened at $4.08 on Thursday. VIVUS has a one year low of $3.30 and a one year high of $9.90.
VIVUS (NASDAQ:VVUS) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.11) by $0.24. The firm had revenue of $18.09 million for the quarter. Equities research analysts expect that VIVUS will post -4.4 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC lifted its position in shares of VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the quarter. Renaissance Technologies LLC owned about 7.79% of VIVUS worth $5,833,000 as of its most recent SEC filing.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Featured Story: Intrinsic Value
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.